Xenon Pharmaceuticals Inc.
XENE
Peringkat dalam Saham
#4417
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company... Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
Harga Saham
$36.43
Kapitalisasi Pasar
$3.53B
Perubahan (1 hari)
3.85%
Perubahan (1 tahun)
-16.13%
Negara
CA
Perdagangan Xenon Pharmaceuticals Inc. (XENE)
Kategori
Healthcare
Laba untuk Xenon Pharmaceuticals Inc. (XENE)
Laba pada Jun 2026 TTM: $-411.14M
Menurut laporan keuangan terbaru dari Xenon Pharmaceuticals Inc., laba saat ini perusahaan adalah $-411.14M. Pada tahun 2023, perusahaan memperoleh laba sebesar $-182.69M, penurunan dibandingkan dengan laba tahun 2022 sebesar $-125.26M. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Xenon Pharmaceuticals Inc. dari 2011 hingga 2026
Laba pada akhir setiap tahun
| Tahun | Laba | Mengubah |
|---|---|---|
| 2026 (TTM) | $-411.14M | 72.44% |
| 2024 | $-238.42M | 30.51% |
| 2023 | $-182.69M | 45.85% |
| 2022 | $-125.26M | 58.78% |
| 2021 | $-78.89M | 171.15% |
| 2020 | $-29.09M | -30.09% |
| 2019 | $-41.62M | 20.64% |
| 2018 | $-34.50M | 12.35% |
| 2017 | $-30.70M | 33.51% |
| 2016 | $-23.00M | 45.99% |
| 2015 | $-15.75M | -221.00% |
| 2014 | $13.02M | 8.19% |
| 2013 | $12.03M | -379.75% |
| 2012 | $-4.30M | -64.13% |
| 2011 | $-11.99M | 0.00% |
Laba untuk perusahaan serupa atau pesaing
| Perusahaan | Laba | Perbedaan Laba | Negara |
|---|---|---|---|
| $5.27B | -1,383.01% |
US
|
|
| $-3.09B | 650.85% |
US
|
|
| $-4.02B | 876.85% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -574.45% |
NL
|
